Yoon Hang "John" Kim, MD - Getting the most of LDN treatment and Beyond LDN (2019 Conference) (LDN, low dose naltrexone)
LDN therapy has become more accepted in medicine. However, many practitioners of LDN therapy operate from the conventional wisdom of LDN for autoimmune disorders using 1.5 mg to 4.5 mg. However, the original article interviewing Dr. Bihari focus on LDN as an agent that can normalize immune system. Recent articles point to the mechanism by which normalizing immune system including modulation of glial cell function via Toll like receptor 4 (TLR4). Understanding the mechanism of TLR4 opens up whole new clinical implications not considered at this time. The clinical use for utilizing ultra low dose naltrexone or microgram dosing of naltrexone will be reviewed.
Session Learning Objective:
- To demonstrate the mechanism of immune system normalization through glial cell modulation.
- Understanding LDN as a TLR4 receptor antagonist
- To state new clinical treatment possibilities with LDN
- State when to use microgram dosing of naltrexone